Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Temporarily not available × pembrolizumab × Clear all

Status

Completed 556 Recruiting 504 Active not recruiting 369 Terminated 268 Unknown 122 Withdrawn 89 Not yet recruiting 74 Suspended 6 No longer available 3 Temporarily not available 1 Enrolling by invitation 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Conditions

KRAS G12V Mutant Advanced Epithelial Cancers 1

Interventions

Gemcitabine 2 pembrolizumab 1 Taxes 1 Insulin Infusion Systems 1 FANG vaccine 1 Erlotinib Hydrochloride 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05389514 2025-11-20

Intermediate-size IND for Treatment of KRAS G12V-mutant Tumors

Providence Health & Services

Temporarily not available

KRAS G12V Mutant Advanced Epithelial Cancers

Data powered by HemOnc (CC BY 4.0) Colophon ⚡